Navigation Links
Thomson Reuters Publishes Pharma Matters White Paper, 'The Five Myths of Generic Competition'
Date:3/10/2009

Unique Survey Shows Much Room for Originator Pharmaceutical Companies to Improve Their Understanding of Generic Competition

PHILADELPHIA and LONDON, March 11 /PRNewswire/ -- The Healthcare and Science business of Thomson Reuters today released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.

The findings in this white paper are based on an independent survey of commercial professionals in pharmaceutical and biotech companies. The research was conducted by Thomson Reuters during May and June 2008.

The survey highlights a number of prevailing attitudes among commercial professionals, including:

  • Commercial professionals believe that little can be done to prevent sales erosion by generic drugs.
  • Commercial professionals feel that originator companies have little time or resources to devote to understanding generic competition.
  • Most executives surveyed assume that such research is already being conducted by someone else in their organization.

"The intelligence gathered and analyzed by our researchers tells us that these attitudes are based on some false assumptions," says Claude Basset, VP Specialty Markets, Thomson Reuters. "Understanding and forecasting generic competition remains undoubtedly a serious strategic challenge for anyone with a brand product on the market. It's clear, however, that there is more originators could do better - and earlier - to prepare for generic competition."

In analyzing the study findings, Thomson Reuters offers guidance on when and how best to improve competitive intelligence processes by focusing on more effective sources of long-range signals, and by providing brand teams with the resources and tools necessary to better understand generic competition.

To learn more about how companies can improve their understanding and forecasting of generic competition, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/generic_myths.pdf

"The Five Myths of Generic Competition" is part of Pharma Matters, a quarterly report series from Thomson Reuters that covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Newport Vision Premium(TM), Thomson Pharma(R), and the Thomson Messaging Mapping System(SM).

To sign up for the Thomson Reuters Pharma Matters series of publications visit:

http://scientific.thomsonreuters.com/info/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Reuters Study Tracks Impact of Recession on Hospitals
2. VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems
3. Molecular Oncology accepted into Thomson Reuters index
4. Thomson Reuters Releases 2009 Patent Focus Report
5. Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study
6. Thomson Reuters Launches Liquent PublishPerfect(TM)
7. CMS Selects Thomson Reuters to Help Implement Medicare Medical Home Demonstration Project for Medicare Recipients
8. Thomson Reuters Installs Clinical Xpert at Catholic Healthcare West for HIS Downtime Solution
9. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
10. Tomball Regional Medical Center Selects Clinical Xpert(TM) from Thomson Reuters to Lead Quality Improvement Initiatives
11. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... , ... Warren L. Smith M.D. , There is a new tool in ... since the beginning of recorded medical history, and in spite of all the antibiotics ... a matter of inconvenience; bladder infections cost us billions of dollars annually in lost ...
(Date:5/4/2016)... ... May 04, 2016 , ... DESCO Medical Service, ... Sterilizer, an equipment sterilization service and sales company located in Pennsylvania. The terms ... research-related equipment and asset management services to the medical and academic research industries. ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... provider, certified that their Vasont Universal Integrator (VUI) extension supports the latest release ... release of Adobe FrameMaker 2015 interlace the process of creating, editing and storing ...
(Date:5/3/2016)... ... ... The National Association of Professional Women (NAPW) honors Barbara ... She is recognized with this prestigious distinction for leadership in business. NAPW is the ... over 200 operating Local Chapters. , “I’m pleased to welcome Barbara into this exceptional ...
(Date:5/3/2016)... ... May 03, 2016 , ... Today at its Annual Technology ... D. Pulido, R.Ph., Co-Founder of NCPDP and member of the NCPDP Foundation Board ... IT Specialist, Office of the National Coordinator for Health Information Technology (ONC). NCPDP’s ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 4, 2016 ... 154 pages, profiling 09 key companies and supported ... professional and in-depth study on the current state ... overview of the industry including definitions, classifications, applications ... analysis is provided for the international market including ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
(Date:5/3/2016)... -- As a teenager, an active and athletic Randy ... heart. He continued enjoying sports and recreation throughout his ... was giving out and he was a few hours ... Mesa, Arizona resident received a ... transplant, the SynCardia TAH-t is the only approved device ...
Breaking Medicine Technology: